Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected. Patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. Patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. Propensity score matching (PSM) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. After pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.
age ≥18 years;
pathological diagnosis of esophageal squamous cell carcinoma;
failure to undergo surgical treatment;
completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy.
history of other malignant tumors;
difficulty in follow-up;
insufficient clinical information.
Patients with esophageal squamous carcinoma who received concurrent chemoradiotherapy with or without trilaciclib.
Cohort
Retrospective
Trilaciclib Injection [Cosela]
DrugTrilaciclib Combined chemoradiotherapy
Incidence of grade ≥3 neutropenia
Incidence of grade ≥3 neutropenia
Incidence of Adverse Events
The incidence of Adverse Events according to Common Terminology Criteria for Adverse Events
Click on the lead sponsor to view all of their trials.
